60 Degrees Pharmaceuticals (SCTP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Jun, 2026Executive summary
The annual meeting will be held virtually on August 5, 2026, with voting available by telephone or mail for shareholders of record as of July 2, 2026.
Proxy materials are distributed primarily via the internet to expedite delivery, reduce costs, and conserve resources.
The Board recommends voting in favor of all proposals, including director elections, equity plan amendments, a reverse stock split, auditor ratification, a management success fee, and potential adjournment to solicit more proxies.
Voting matters and shareholder proposals
Shareholders will vote on electing five directors, amending the 2022 Equity Incentive Plan to add 800,000 shares, a reverse stock split (1:5 to 1:10), ratifying RBSM LLP as auditor, approving a management success fee, and adjourning the meeting if needed.
The Board recommends a "FOR" vote on all proposals.
No other business is expected at the meeting, and no shareholder nominations were received.
Board of directors and corporate governance
The Board consists of five directors, three of whom are independent under Nasdaq rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with written charters.
The Board met six times in 2025, with high attendance and regular executive sessions for non-management directors.
The Nominating and Corporate Governance Committee considers diversity and experience in director selection.
Corporate governance materials, including the Code of Conduct, are available on the company website.
Latest events from 60 Degrees Pharmaceuticals
- Registering 1.77M shares for resale, with focus on infectious disease therapies and Arakoda expansion.SCTP
Registration filing - Q2 revenue doubled year-over-year, but losses and cash burn raise going concern risks.SCTP
Q2 2026 - ARAKODA drives growth in malaria and babesiosis markets, with profitability targeted by 2028.SCTP
Investor presentation - Shareholders will vote on director elections, equity plan expansion, a reverse split, and key governance items.SCTP
Proxy filing - Net loss widened to $2.21 million as revenues and gross margin declined in Q1 2026.SCTP
Q1 2026 - Clinical and commercial advances in babesiosis could multiply sales far beyond malaria.SCTP
Biotech Resurgence: Platforms and Pipelines of Today's Innovators - 2025 revenue grew 65%, but losses and a going concern warning persist amid higher costs.SCTP
Q4 2025 - Offering up to $15M in securities to fund infectious disease pipeline and Arakoda expansion.SCTP
Registration Filing - Sales growth and clinical trials position ARAKODA for expanded use and major milestones by 2026.SCTP
H.C. Wainwright 27th Annual Global Investment Conference